Sotyktu
Generic name: Deucravacitinib
Dosage form: tablets
Drug class:
Multikinase inhibitors
Usage of Sotyktu
Sotyktu (deucravacitinib) is a prescription medicine that is a once-daily tablet used to treat adults with moderate to severe plaque psoriasis, that is suitable for systemic therapy or phototherapy.
Sotyktu belongs to a new class of drugs called tyrosine kinase 2 (TYK2) inhibitors that works by blocking a protein called TYK2.
TYK2 is part of the immune system that has a role in inflammation and can cause plaque psoriasis. Blocking TYK2 improves symptoms of psoriasis, by reducing the severity and amount of psoriasis lesions.
Sotyktu side effects
Sotyktu may cause serious side effects, including:
See Important information.
Changes in certain laboratory test results. Changes in laboratory tests have happened in some people taking Sotyktu. Your healthcare provider may do blood tests before you start, and during treatment to check for the following:
Potential risks from Janus kinase (JAK) inhibition. Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor. TYK2 is in the JAK family . It is not known whether taking Sotyktu has the same risks as taking JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least one heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. Sotyktu is not for use in people with RA.
The most common side effects include:
These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Sotyktu
You should not take Sotyktu if you are allergic to deucravacitinib or any of the other ingredients. See the end of this page for a complete list of ingredients.
Relate drugs
- Afatinib
- Alecensa
- Alectinib
- Alunbrig
- Avapritinib
- Ayvakit
- Cobimetinib
- Cotellic
- Crizotinib
- Balversa
- Binimetinib
- Braftovi
- Brigatinib
- Capmatinib
- Ceritinib
- Dabrafenib
- Deucravacitinib
- Encorafenib
- Entrectinib
- Erdafitinib
- Fedratinib
- Futibatinib
- Gavreto
- Gilotrif
- Gilteritinib
- Infigratinib
- Inrebic
- Jakafi
- Koselugo
- Larotrectinib
- Litfulo
- Lorbrena
- Lorlatinib
- Lytgobi
- Mekinist
- Mektovi
- Midostaurin
- Momelotinib
- Nintedanib
- Ofev
- Ojjaara
- Pacritinib
- Pemazyre
- Pemigatinib
- Pexidartinib
- Pralsetinib
- Qinlock
- Retevmo
- Ripretinib
- Ritlecitinib
- Rozlytrek
- Ruxolitinib
- Ruxolitinib (Oral)
- Rydapt
- Selpercatinib
- Selumetinib
- Sotyktu
- Tabrecta
- Tafinlar
- Tepmetko
- Tepotinib
- Trametinib
- Truseltiq
- Turalio
- Ukoniq
- Umbralisib
- Vemurafenib
- Vitrakvi
- Vonjo
- Xalkori
- Xospata
- Zelboraf
- Zykadia
How to use Sotyktu
Usual Adult Dose for Plaque Psoriasis:
- 6 mg orally once daily.
Use: treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Warnings
Sotyktu may cause serious side effects, including:
Serious allergic reactions. Stop treatment and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
Infections. Sotyktu is a medicine that affects your immune system. Sotyktu can lower the ability of your immune system to fight infections and can increase your risk of infections. Some people have had serious infections while taking Sotyktu, such as infections of the lungs, including pneumonia and tuberculosis (TB), and COVID-19.
Sotyktu should not be used in people with an active, serious infection, including localized infections. You should not start taking Sotyktu if you have any kind of infection unless your healthcare provider tells you it is okay.
You may be at a higher risk of developing shingles (herpes zoster).
Before you start treatment, tell your healthcare provider if you:
After you start taking Sotyktu, call your healthcare provider right away if you have an infection or have symptoms of an infection. Sotyktu can make you more likely to get infections or make any infections you have worse.
Cancer. Certain kinds of cancer including lymphoma have been reported in people taking Sotyktu.
Muscle problems (rhabdomyolysis). Sotyktu can cause muscle problems that can be severe. Treatment with Sotyktu may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Increased CPK is common in people taking Sotyktu. Your healthcare provider may tell you to stop taking Sotyktu if the amount of CPK in your blood gets too high or if you have signs and symptoms of severe muscle problems.
Tell your healthcare provider right away if you have any of these signs or symptoms of severe muscle problems:
See Sotyktu side effects for more information about side effects.
What other drugs will affect Sotyktu
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.
Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions